Results 81 to 90 of about 3,726 (180)

Managing Monitoring: Biologic Therapy for Psoriasis

JEADV Clinical Practice, Volume 5, Issue 2, Page 695-697, June 2026.
Claudine Howard‐James, Eimear Gilhooley   +1 more
wiley   +1 more source

Transcription Factor IRF7 is Involved in Psoriasis Development and Response to Guselkumab Treatment

Journal of Inflammation Research
Xiuqing Yuan,1,* Tiantian Xin,1,* Huanhuan Yu,1 Jian Huang,2 Yaohan Xu,1 Caixin Ou,1 Yongfeng Chen1 1Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong Province, People’s Republic of China ...
Yuan X, Xin T, Yu H, Huang J, Xu Y, Ou C, Chen Y   +6 more
doaj  

Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 Study

Rheumatology and Therapy
Introduction The aim of this study was to evaluate guselkumab efficacy through week 100 in participants with psoriatic arthritis (PsA) and severe disease activity or patient global assessment (PtGA).
Christopher T. Ritchlin, Ennio Lubrano, Maria Sole Chimenti, Evan Leibowitz, Mohamed Sharaf, Emmanouil Rampakakis, Francois Nantel, Frederic Lavie, Atul Deodhar   +8 more
doaj   +1 more source

Ausgeprägte und disseminierte atypische Mykobakteriose der Haut unter Immunsuppression

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 6, Page 806-809, June 2026.
Veronika Zenderowski, Laura Schreieder, Mark Berneburg, Dennis Niebel, Sebastian Haferkamp, Sigrid Karrer, Konstantin Drexler   +6 more
wiley   +1 more source

Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials

Rheumatology and Therapy
Introduction There are limited data on the use of advanced therapies to treat psoriatic arthritis (PsA) in Russia. Guselkumab, an interleukin (IL)-23p19-subunit inhibitor, demonstrated efficacy in patients with PsA in the phase 3 DISCOVER-1 and -2, and ...
Philip Mease, Tatiana Korotaeva, Pavel Shesternya, Muza Kokhan, Anton Rukavitsyn, Dmitry Vasilchenkov, Mohamed Sharaf, Frédéric Lavie, Atul Deodhar   +8 more
doaj   +1 more source

A case of concomitant hidradenitis suppurativa and psoriasis successfully treated with guselkumab in a patient with Down syndrome

Turkderm Turkish Archives of Dermatology and Venereology
In this case report, we present a 29-year-old patient with Down syndrome (DS) who manifested both psoriasis and hidradenitis suppurativa (HS) concurrently.
Simge Ünal, Tuğcan Yüksek
doaj   +1 more source

Severe and disseminated atypical mycobacteriosis of the skin under immunosuppression

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 6, Page 806-808, June 2026.
Veronika Zenderowski, Laura Schreieder, Mark Berneburg, Dennis Niebel, Sebastian Haferkamp, Sigrid Karrer, Konstantin Drexler   +6 more
wiley   +1 more source

On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies

Journal of Dermatological Treatment
Objective To compare on-label persistence among adults with psoriasis who switched from other advanced therapies to guselkumab versus subcutaneous tumor necrosis factor inhibitors (SC TNFi), subcutaneous interleukin-17 inhibitors (SC IL-17i), or ...
Maryia Zhdanava, Timothy Fitzgerald, Porpong Boonmak, Dominic Pilon, Samuel Schwartzbein, Béatrice Libchaber, Steven R. Feldman   +6 more
doaj   +1 more source

Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis)

Dermatology and Therapy
Introduction Guselkumab is a monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, approved for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis (PsA).
Mario Valenti, Luciano Ibba, Sara Di Giulio, Paolo Dapavo, Piergiorgio Malagoli, Angelo V. Marzano, Francesco Loconsole, Martina Burlando, Anna Balato, Valentina Dini, Matteo Megna, Giampiero Girolomoni, Emanuele Trovato, Claudia Lasagni, Massimo Travaglini, Claudio Guarneri, Nicola Zerbinati, Simone Ribero, Francesca M. Gaiani, Carlo G. Carrera, Emanuele C. Cozzani, Eugenia V. Di Brizzi, Alessandra Michelucci, Luca Potestio, Martina Maurelli, Martina Dragotto, Luca Mastorino, Eleonora Bongiovanni, Francesco Messina, Andrea Sechi, Rossana Moroni, Antonio Costanzo, Alessandra Narcisi   +32 more
doaj   +1 more source

Guselkumab (Tremfya) [PDF]

Dermatologie pro praxi, 2020
Jan Hugo, Spyridon Gkalpakiotis
openaire   +1 more source